$BIIB

Biogen shares rise 1.06% to $193.40 despite FDA extending Leqembi review to August 2026, offset by $5.6B Apellis acquisition and Spinraza approval momentum.

FDA extends LEQEMBI IQLIK subcutaneous review to August 2026 without raising approvability concerns, maintaining regulatory momentum for Eisai and Biogen's reformulated Alzheimer's treatment.

IgA Nephropathy market projects 18.6% CAGR through 2036 from $1.5B base, driven by novel immunotherapies and recent FDA approvals reshaping kidney disease treatment.

Biogen's three-decade outperformance is challenged by biosimilar competition and weak growth, though new Alzheimer's and rare disease drugs offer hope. Success requires flawless execution.

Trump signs S. 3971 extending SBIR-STTR programs through 2031. Programs have invested $81 billion supporting 34,000+ small businesses.

Global dementia market expanding rapidly as disease-modifying treatments like LEQEMBI and KISUNLA shift focus from symptom management to early intervention for 55 million affected patients worldwide.

Biogen partners with Alloy Therapeutics to advance antisense oligonucleotide therapies using the AntiClastic platform for multiple undisclosed disease indications.

IMN market expected to grow nearly 8x from $130M in 2025 to $1B by 2036, driven by novel therapies addressing unmet treatment needs.

McCormick merges with Unilever Foods for $29.1B while Sysco acquires Jetro for $29B; QVC explores bankruptcy amid retail distress.

Over 120 pharmaceutical companies are developing 140+ drugs for systemic lupus erythematosus, with major players like Roche and Novartis advancing promising new treatment mechanisms.

S&P 500 surges 1.8% on Trump's Iran peace signals; Nasdaq 100 rises 2%. Despite rally, index down 6.2% monthly toward worst month since September 2022.

Biogen acquires Apellis Pharmaceuticals for $5.6 billion in cash, gaining two FDA-approved therapies with $689M in 2025 projected sales and mid-to-high teens growth expectations.

$BIOG rallies as FDA approves high-dose Spinraza for spinal muscular atrophy, while litifilimab shows positive Phase 2 lupus results.

Biogen announces second positive Phase 2 trial of litifilimab for cutaneous lupus, showing 11.8% greater disease reduction than placebo, advancing toward potential first targeted CLE therapy in 70 years.

Federal court certifies class action against Biogen for alleged 2021 securities misrepresentations, affecting purchasers during June-July period.

ALS therapeutics market to more than double by 2035, reaching $1.96 billion. Growth driven by genetic therapies, improved diagnostics, and disease awareness.

Alzheimer's therapeutics market projected to exceed $6B by 2026 driven by rising disease prevalence and increased pharma investment in disease-modifying treatments.